Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATSA: LA-SSA Timing in PRRT
NCT06855095Phase 3Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2024
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Neuroendocrine Neoplasm (NEN) (3 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Absorbed dose in tumor lesions. Started Jun 2024; status: recruiting.
02
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT06855095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06855095.